StoneX Group Inc. Has $1.53 Million Stock Position in Pfizer Inc. (NYSE:PFE)

StoneX Group Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 1.6% in the third quarter, HoldingsChannel reports. The fund owned 52,981 shares of the biopharmaceutical company’s stock after selling 836 shares during the period. StoneX Group Inc.’s holdings in Pfizer were worth $1,533,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. KKM Financial LLC increased its position in Pfizer by 5.4% in the third quarter. KKM Financial LLC now owns 73,671 shares of the biopharmaceutical company’s stock worth $2,132,000 after purchasing an additional 3,767 shares during the period. Palisade Asset Management LLC boosted its stake in shares of Pfizer by 2.6% in the 3rd quarter. Palisade Asset Management LLC now owns 50,235 shares of the biopharmaceutical company’s stock valued at $1,454,000 after purchasing an additional 1,295 shares during the last quarter. Canopy Partners LLC grew its position in shares of Pfizer by 4.9% during the 3rd quarter. Canopy Partners LLC now owns 34,588 shares of the biopharmaceutical company’s stock worth $1,001,000 after buying an additional 1,618 shares during the period. Cerity Partners LLC raised its stake in shares of Pfizer by 26.2% during the third quarter. Cerity Partners LLC now owns 1,984,016 shares of the biopharmaceutical company’s stock worth $57,417,000 after buying an additional 412,364 shares during the last quarter. Finally, Waddell & Associates LLC lifted its holdings in Pfizer by 1.6% in the third quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company’s stock valued at $723,000 after buying an additional 388 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 11.11 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Stock Performance

Shares of PFE opened at $25.65 on Monday. The firm has a market cap of $145.36 billion, a P/E ratio of 34.66, a PEG ratio of 0.82 and a beta of 0.67. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm’s 50 day moving average price is $28.21 and its two-hundred day moving average price is $28.57.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.17) EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.55%. Pfizer’s payout ratio is presently 227.03%.

Wall Street Analyst Weigh In

A number of analysts have commented on PFE shares. Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. Citigroup began coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective for the company. UBS Group increased their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.